MHRA Updates Quarter 3 2019
Updates from the MHRA for the third quarter of 2019
- Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in patients with a history of major cardiovascular disease
- Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food
- Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus
- Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive
- Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
- Fingolimod (Gilenya▼): New contraindications due to increased risk of congenital malformations
- Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy leading to visual impairment
- Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions
You can sign up to receive alerts directly at: MHRA email alerts
Published 15/01/2020. Medicines Update blogs are correct at the time of publication.